Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NUS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Goodwill Impairment (new) — The company recorded $78.9M in impairment charges in Q2 2026, contributing to a GAAP operating loss.
- Material Weakness (new) — A $167.5M valuation allowance was recorded against deferred tax assets, indicating uncertainty about future taxable income.
Nu Skin reports Q2 revenue down 17%, posts $5.14 loss on impairment and tax charges
Filed August 10, 2026 · Period ending August 10, 2026 · ~1 min read
Key Changes
-
high
Q2 revenue fell 17% to $320.1M; GAAP loss of $5.14/share driven by $78.9M goodwill impairment and $167.5M deferred tax valuation allowance (adjusted EPS $0.20 vs. $0.43 prior year)
Exhibit 99.1 view on EDGAR → -
high
Sales force contracted: customers down 14% to 660,037, paid affiliates down 8% to 120,291, sales leaders down 9% to 26,998
Exhibit 99.1 view on EDGAR → -
high
Full-year 2026 guidance lowered to $1.28B–$1.35B revenue (down 14%–9%) and adjusted EPS of $0.70–$0.90
Exhibit 99.1 view on EDGAR → -
high
$167.5M valuation allowance recorded against deferred tax assets, signaling uncertainty about future taxable income
Exhibit 99.1 view on EDGAR → -
medium
Q3 2026 outlook: revenue $310M–$340M (down 15%–7%), adjusted EPS $0.10–$0.20, with ~$5M in transition costs expected
Exhibit 99.1 view on EDGAR →
Summary
Nu Skin disclosed a challenging second quarter marked by accelerating revenue declines and significant non-cash charges. Revenue fell 17% year-over-year to $320.1 million, driven by a 14% contraction in the customer base and high-single-digit declines in both paid affiliates and sales leaders.
The company posted a GAAP loss of $5.14 per share, reflecting $78.9 million in goodwill impairment and a $167.5 million valuation allowance against deferred tax assets. Excluding these charges, adjusted EPS was $0.20, down from $0.43 in the prior-year quarter.
The deferred tax valuation allowance is particularly concerning, as it signals management's assessment that the company may not generate sufficient future taxable income to realize existing tax benefits. Combined with the goodwill impairment, these charges point to a business under structural pressure. Management lowered full-year guidance to $1.28 billion–$1.35 billion in revenue (down 9%–14%) and adjusted EPS of $0.70–$0.90, with Q3 expected to show continued revenue declines of 7%–15%. The persistent contraction in the sales force and customer base suggests ongoing challenges in recruiting and retention across most markets.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Nu Skin announced Q2 2026 financial results via press release; detailed figures not disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
On August 10, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2026, and certain other information.
The company disclosed its second quarter and first half 2026 financial results through a press release. The 8-K body does not contain the actual financial figures; those appear in the attached Exhibit 99.1 press release.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Revenue | $320.1 million; (17.1)% | • (1.0)% FX impact or $(4.0) million | Earnings Per Share (EPS) $(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Nu Skin reported Q2 2026 revenue of $320.1 million, down 17.1% year-over-year (16.1% on a constant-currency basis). GAAP EPS was a loss of $5.14, driven by $78.9 million in impairment charges and a $167.5 million valuation allowance on deferred tax assets. Excluding these non-cash items, adjusted EPS was $0.20, down from $0.43 in Q2 2025.
Added in current filing · view on EDGAR →
2026 Revenue | $1.28 to $1.35 billion; (14)% to (9)% | • Approximately (1)% FX impact | 2026 EPS ($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis
Nu Skin lowered its full-year 2026 guidance. The company now expects revenue of $1.28 billion to $1.35 billion (down 14% to 9% year-over-year) and GAAP EPS of negative $4.90 to negative $4.73. On an adjusted basis, excluding impairment and tax charges, the company expects EPS of $0.70 to $0.90.
Added in current filing · view on EDGAR →
Q3 2026 Revenue | $310 to $340 million; (15)% to (7)% | • Approximately (3) to (2)% FX impact | Q3 2026 EPS $0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
For Q3 2026, Nu Skin expects revenue of $310 million to $340 million (down 15% to 7% year-over-year) and GAAP EPS of $0.00 to $0.09. On an adjusted basis, the company expects EPS of $0.10 to $0.20. The company anticipates approximately $5 million in cash-based transition costs in Q3.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 11, 2026 · How we verify